scholarly journals Current Status of Castration-Resistant Prostate Cancer Drug Therapy

2021 ◽  
Vol 6 (1) ◽  
pp. 41-49
Author(s):  
Yifeng Mao ◽  
Mingqiu Hu ◽  
Gaowei Yang ◽  
Erke Gao ◽  
Wenbang Chen
Keyword(s):  
Prostate Cancer ◽  
Drug Therapy ◽  
Current Status ◽  
Cancer Drug ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review

2020 ◽  
Vol 21 (15) ◽  
pp. 5484 ◽  
Author(s):  
Tae Jin Kim ◽  
Kyo Chul Koo
Keyword(s):  
Prostate Cancer ◽  
Solid Tumors ◽  
Treatment Modality ◽  
Cytotoxic Agents ◽  
Therapeutic Modality ◽  
Current Status ◽  
Molecular Diagnostic ◽  
Castration Resistant Prostate Cancer ◽  
Androgen Synthesis ◽  
Castration Resistant

The clinical spectrum of prostate cancer (PCa) varies from castration-naive to metastatic castration-resistant disease. Despite the administration of androgen synthesis inhibitors and chemotherapy regimens for castration-resistant prostate cancer, the treatment options for this entity are limited. The utilization of the immune system against cancer cells shows potential as a therapeutic modality for various solid tumors and hematologic malignancies. With technological advances over the last decade, immunotherapy has become an integral treatment modality for advanced solid tumors. The feasibility of immunotherapy has shown promise for patients with PCa, and with advances in molecular diagnostic platforms and our understanding of immune mechanisms, immunotherapy is reemerging as a potential treatment modality for PCa. Various combinations of individualized immunotherapy and immune checkpoint blockers with androgen receptor-targeted therapies and conventional cytotoxic agents show promise. This article will review the current status of immunotherapy, including new discoveries and precision approaches to PCa, and discuss future directions in the continuously evolving landscape of immunotherapy.

Drug therapy methods in patients with metastatic castration-resistant prostate cancer: Role of somatostatin analogues

2017 ◽  
Vol 6 (3) ◽  
pp. 76
Author(s):  
A. A. Krasheninnikov ◽  
K. M. Nyushko ◽  
E. Yu. Safronova ◽  
A. S. Kalpinsky ◽  
A. A. Kostin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Therapy ◽  
Somatostatin Analogues ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

CASTRATION-RESISTANT PROSTATE CANCER: NEW PERSPECTIVES IN PHARMACOLOGICAL TREATMENT

2019 ◽  
Vol 25 (1) ◽  
pp. 49-58
Author(s):  
Dmitry A. Andreev ◽  
A. A Zavyalov ◽  
A. V Govorov ◽  
K. A. Kokushkin ◽  
M. Y Davidovskaya
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
Treatment Options ◽  
Specific Treatment ◽  
Cochrane Library ◽  
Cancer Drug ◽  
Castration Resistant Prostate Cancer ◽  
Optimal Sequence ◽  
Treatment Algorithms ◽  
Castration Resistant

Prostate cancer remains one of the most actual problems in oncourology due to its high prevalence and resistance to therapy. Within 5 years of active treatment and follow-up, the castration-resistant prostate cancer (CRPC) develops in 10-20% of patients. This type of disease course resists treatments and leads to death. Medical resources distinguish two different forms of CRPC: non-metastatic and metastatic. Such separation is critically important because each of two forms requires different treatment algorithms. This paper summarizes the main outlines of foreign clinical guidelines and reviews the new treatment options for non-metastatic and metastatic CRPC as wells as the design and results of key clinical trials on drug efficiency. To prepare the review, the comprehensive literature search was conducted using PubMed/Medline, the Cochrane Library, EMBASE, CyberLeninka, e-library databases. The search line included phrases containing the following words: prostate cancer, castration-resistant prostate cancer, drug therapy, treatment algorithms, clinical studies, etc. In accordance to foreign guidelines, it is essential to determine the high risk patients with non-metastatic CRPC and promptly apply new therapeutic options including apalutamide and enzalutamide, which have proven being effective in clinical trials as therapies that attenuate the transition of the non-metastatic CRPC to the metastatic stage. Foreign medical guidelines propose to apply a wider set of treatment algorithms for patients with metastatic CRPC, for instance: considerations on possibilities to use the cabazitaxel instead of docetaxel in the 1st line therapy in patients with pre-existing mild peripheral neuropathy, etc. as well as new therapies - pembrolizumab and sipuleucel-T. The issues regarding the selection of patients with CRPC for specific treatment algorithms and defining the optimal sequence of therapeutic regimens as well as combining various regimens with minimizing toxic effects and maximizing patient benefits remain unsolved.

Prescribing practices for tumour aggressiveness and castration resistance in risk-stratified prostate cancer patients

2020 ◽  
Vol 2 (7) ◽  
pp. 392-397
Author(s):  
Meenakshi Meenu ◽  
Dharamvir Singh Arya
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Essential Medicines ◽  
World Health ◽  
Cancer Drug ◽  
Prescription Data ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistance ◽  
Prescribing Practices ◽  
Castration Resistant

Capturing real-world prescription data is important for evaluating clinical practice in prostate cancer. The aim of this study was to evaluate prescribing practices in prostate cancer. This was a cross-sectional study in which four groups were identified based on tumour aggressiveness (bone metastasis absent and bone metastasis presnt) and castration response (castration-sensitive prostate cancer and castration-resistant prostate cancer). Drug utilisation methodology and core indicators of World Health Organization were used. A total of 150 patients were stratified into the four groups. The most common regime was complete androgen blockade in both bone metastasis groups and castration-sensitive prostate cancer. Palliative radiotherapy was part of the management in the bone metastasis (present) group. In castration-resistant prostate cancer, abiraterone, fosfestrol, docetaxel, and enzalutamide were prescribed. Approximately 78% of prescriptions contained medicines from the National List of Essential Medicines, India, 2015. Polypharmacy was not a common practice, antibiotics and antidepressant medicines were rarely prescribed. The prescribing trend for prostate cancer conformed to National Comprehensive Cancer Network guidelines.

scholarly journals Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3715
Author(s):  
Konstantin Egon Seitzer ◽  
Robert Seifert ◽  
Katharina Kessel ◽  
Wolfgang Roll ◽  
Katrin Schlack ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Adverse Events ◽  
Current Status ◽  
Castration Resistant Prostate Cancer ◽  
Future Perspectives ◽  
Radioligand Therapy ◽  
Castration Resistant ◽  
Current State ◽  
Disease Stages ◽  
Specific Membrane

Patients suffering from metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis. As a further treatment option 177Lutetium (Lu) prostate-specific membrane antigen (PSMA) radioligand therapy gained a significant interest of many investigators. Several publications showed great response and prolonged survival with limited adverse events. However, to this point, it still remains unclear which patients benefit the most from 177Lu-PSMA therapy, and how to improve the treatment regimen to achieve best outcome while minimizing potential adverse events. The efficacy for mCRPC patients is a given fact, and with the newly published results of the VISION trial its approval is only a matter of time. Recently, investigators started to focus on treating prostate cancer patients in earlier disease stages and in combination with other compounds. This review gives a brief overview of the current state and the future perspectives of 177Lu labelled PSMA radioligand therapy.

scholarly journals Global experience with PSMA-based alpha therapy in prostate cancer

2021 ◽  
Author(s):  
Mike M. Sathekge ◽  
Frank Bruchertseifer ◽  
Mariza Vorster ◽  
Alfred Morgenstern ◽  
Ismaheel O. Lawal
Keyword(s):  
Prostate Cancer ◽  
Mechanisms Of Action ◽  
Current Status ◽  
Prostate Specific Membrane Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Current State ◽  
Specific Membrane ◽  
Alpha Therapy ◽  
Physician Scientists

Abstract Purpose This review discusses the current state of prostate-specific membrane antigen (PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC). With this in-depth discussion on the growing field of PSMA-based alpha therapy (PAT), we aimed to increase the interactions between basic scientists and physician–scientists in order to advance the field. Methods To achieve this, we discuss the potential, current status, and opportunities for alpha therapy and strategies, attempted to date, and important questions that need to be addressed. The paper reviews important concepts, including whom to treat, how to treat, what to expect regarding treatment outcome, and toxicity, and areas requiring further investigations. Results There is much excitement about the potential of this field. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other conventional therapies. Conclusion A better understanding of the strengths and limitations of PAT may help in creating an effective therapy for mCRPC and design a rational combinatorial approach to treatment by targeting different tumor pathways.

Sign in / Sign up

Export Citation Format

Share Document